1 World Health Organization. Global Health Observatory. Geneva: World Health Organization; 2018. who.int/gho/database/en/. Accessed June 21, 2018.
2 Sharma, P., Wagner, K., Wolchok, J. D. & Allison, J. P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11, 805-812, doi:10.1038/nrc3153 (2011).
3 Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342, 1432-1433, doi:10.1126/science.342.6165.1432 (2013).
4 Armand, P. et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol 34, 3733- 3739, doi:10.1200/JCO.2016.67.3467 (2016).
5 Borghaei, H. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small- Cell Lung Cancer. N Engl J Med 373, 1627-1639, doi:10.1056/NEJMoa1507643 (2015).
6 El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492-2502, doi:10.1016/S0140-6736(17)31046-2 (2017).
7 Ferris, R. L. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 375, 1856-1867, doi:10.1056/NEJMoa1602252 (2016).
8 Le, D. T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372, 2509-2520, doi:10.1056/NEJMoa1500596 (2015).
9 Nghiem, P. T. et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 374, 2542-2552, doi:10.1056/NEJMoa1603702 (2016).
10 Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711-723, doi:10.1056/NEJMoa1003466 (2010).
11 Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366, 2443-2454, doi:10.1056/NEJMoa1200690 (2012).
12 Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372, 320-330, doi:10.1056/NEJMoa1412082 (2015).
13 Prasad, V. & Kaestner, V. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol 44, 132-135, doi:10.1053/j.seminoncol.2017.06.007 (2017).
14 Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24, 541-550, doi:10.1038/s41591-018-0014-x (2018).
15 Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61, doi:10.1126/science.aaa8172 (2015).
16 Zemek, R. M. et al. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Sci Transl Med 11, doi:10.1126/scitranslmed.aav7816 (2019).
17 Vom Berg, J. et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell- mediated glioma rejection. J Exp Med 210, 2803-2811, doi:10.1084/jem.20130678 (2013).
18 Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19, 1264-1272, doi:10.1038/nm.3337 (2013).
19 Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811, doi:10.1038/35888 (1998).
20 Adams, D. et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med 379, 11-21, doi:10.1056/NEJMoa1716153 (2018).
21 Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46, 6387-6392 (1986).
22 Maeda, H., Sawa, T. & Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74, 47-61, doi:10.1016/s0168- 3659(01)00309-1 (2001).
23 Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S. & La-Beck, N. M. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J Control Release 232, 255-264, doi:10.1016/j.jconrel.2016.04.028 (2016).
24 Nakamura, T., Yamada, Y., Sato, Y., Khalil, I. A. & Harashima, H. Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution. Biomaterials 218, 119329, doi:10.1016/j.biomaterials.2019.119329 (2019).
25 Warashina, S. et al. A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells. J Control Release 225, 183-191, doi:10.1016/j.jconrel.2016.01.042 (2016).
26 Nakamura, T. et al. Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines. Sci Rep 6, 37849, doi:10.1038/srep37849 (2016).
27 Sakurai, Y. et al. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. J Control Release 173, 110-118, doi:10.1016/j.jconrel.2013.10.003 (2014).
28 Sakurai, Y. et al. Remodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100 nm Particles. Mol Ther 24, 2090-2099, doi:10.1038/mt.2016.178 (2016).
29 Hada, T., Sakurai, Y. & Harashima, H. Optimization of a siRNA Carrier Modified with a pH-Sensitive Cationic Lipid and a Cyclic RGD Peptide for Efficiently Targeting Tumor Endothelial Cells. Pharmaceutics 7, 320-333, doi:10.3390/pharmaceutics7030320 (2015).
30 Yamamoto, S., Kato, A., Sakurai, Y., Hada, T. & Harashima, H. Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. J Control Release 251, 1-10, doi:10.1016/j.jconrel.2017.02.010 (2017).
31 Garber, K. A new cancer immunotherapy suffers a setback. Science 360, 588, doi:10.1126/science.360.6389.588 (2018).
32 Hanada, T. et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 19, 437-450, doi:10.1016/s1074- 7613(03)00240-1 (2003).
33 Lee, E. G. et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289, 2350-2354, doi:10.1126/science.289.5488.2350 (2000).
34 Boone, D. L. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5, 1052-1060, doi:10.1038/ni1110 (2004).
35 Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4, 762-774, doi:10.1038/nri1457 (2004).
36 Spranger, S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol 28, 383-391, doi:10.1093/intimm/dxw014 (2016).
37 Munn, D. H. & Bronte, V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol 39, 1-6, doi:10.1016/j.coi.2015.10.009 (2016).
38 Munn, D. H. & Mellor, A. L. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol 37, 193-207, doi:10.1016/j.it.2016.01.002 (2016).
39 Godin-Ethier, J., Hanafi, L. A., Piccirillo, C. A. & Lapointe, R. Indoleamine 2,3- dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17, 6985-6991, doi:10.1158/1078-0432.CCR-11-1331 (2011).
40 Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B. & Muller, A. J. Discovery of IDO1 Inhibitors: From Bench to Bedside. Cancer Res 77, 6795-6811, doi:10.1158/0008- 5472.CAN-17-2285 (2017).
41 Zheng, X. et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer 132, 967-977, doi:10.1002/ijc.27710 (2013).
42 Sioud, M. et al. Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients. Int J Oncol 43, 280-288, doi:10.3892/ijo.2013.1922 (2013).
43 Nakamura, T., Yamada, K., Fujiwara, Y., Sato, Y. & Harashima, H. Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core. Mol Pharm 15, 2142-2150, doi:10.1021/acs.molpharmaceut.7b01166 (2018).
44 Nakamura, T., Yamada, K., Sato, Y. & Harashima, H. Lipid nanoparticles fuse with cell membranes of immune cells at low temperatures leading to the loss of transfection activity. Int J Pharm 587, 119652, doi:10.1016/j.ijpharm.2020.119652 (2020).
45 Chen, W., Liang, X., Peterson, A. J., Munn, D. H. & Blazar, B. R. The indoleamine 2,3- dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 181, 5396-5404, doi:10.4049/jimmunol.181.8.5396 (2008).
46 Wobser, M. et al. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother 56, 1017-1024, doi:10.1007/s00262-006-0256-1 (2007).
47 Zheng, X. et al. RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther 12, R13, doi:10.1186/ar2914 (2010).
48 Rejman, J., Oberle, V., Zuhorn, I. S. & Hoekstra, D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 377, 159-169, doi:10.1042/BJ20031253 (2004).
49 Verma, A. et al. Surface-structure-regulated cell-membrane penetration by monolayer- protected nanoparticles. Nat Mater 7, 588-595, doi:10.1038/nmat2202 (2008).
50 Noh, Y. W., Lim, Y. T. & Chung, B. H. Noninvasive imaging of dendritic cell migration into lymph nodes using near-infrared fluorescent semiconductor nanocrystals. FASEB J 22, 3908-3918, doi:10.1096/fj.08-112896 (2008).
51 Nakamura, T., Moriguchi, R., Kogure, K. & Harashima, H. Incorporation of polyinosine- polycytidylic acid enhances cytotoxic T cell activity and antitumor effects by octaarginine- modified liposomes encapsulating antigen, but not by octaarginine-modified antigen complex. Int J Pharm 441, 476-481, doi:10.1016/j.ijpharm.2012.11.006 (2013).
52 Miyabe, H. et al. A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy. J Control Release 184, 20-27, doi:10.1016/j.jconrel.2014.04.004 (2014).
53 Miura, N., Shaheen, S. M., Akita, H., Nakamura, T. & Harashima, H. A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant. Nucleic Acids Res 43, 1317-1331, doi:10.1093/nar/gkv008 (2015).
54 Fallarino, F. et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176, 6752-6761, doi:10.4049/jimmunol.176.11.6752 (2006).
55 Mezrich, J. D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185, 3190-3198, doi:10.4049/jimmunol.0903670 (2010).
56 Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10, doi:10.1016/j.immuni.2013.07.012 (2013).
57 Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20, 607-615, doi:10.1038/nm.3541 (2014).
58 Sato, Y. et al. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J Control Release 163, 267-276, doi:10.1016/j.jconrel.2012.09.009 (2012).
59 Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830-842, doi:10.1016/j.immuni.2014.10.017 (2014).
60 Burdette, D. L. et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478, 515-518, doi:10.1038/nature10429 (2011).
61 Parvatiyar, K. et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol 13, 1155-1161, doi:10.1038/ni.2460 (2012).
62 Nakamura, T. et al. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J Control Release 216, 149- 157, doi:10.1016/j.jconrel.2015.08.026 (2015).
63 Smedsrød, B. et al. Cell biology of liver endothelial and Kupffer cells. Gut 35, 1509-1516, doi:10.1136/gut.35.11.1509 (1994).
64 De Leeuw, A. M., Brouwer, A. & Knook, D. L. Sinusoidal endothelial cells of the liver: fine structure and function in relation to age. J Electron Microsc Tech 14, 218-236, doi:10.1002/jemt.1060140304 (1990).
65 Griffith, T. S. & Ferguson, T. A. The role of FasL-induced apoptosis in immune privilege. Immunol Today 18, 240-244, doi:10.1016/s0167-5699(97)81663-5 (1997).
66 Saas, P. et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99, 1173-1178, doi:10.1172/JCI119273 (1997).
67 Yang, J. et al. Endothelial cell overexpression of fas ligand attenuates ischemia-reperfusion injury in the heart. J Biol Chem 278, 15185-15191, doi:10.1074/jbc.M211707200 (2003).
68 Suda, T. et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 154, 3806- 3813 (1995).
69 Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6, 273-286, doi:10.1038/nrd2115 (2007).
70 Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342, doi:10.1056/NEJMoa032691 (2004).
71 Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186, doi:10.1056/NEJM197111182852108 (1971).
72 Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8, 579-591, doi:10.1038/nrc2403 (2008).
73 Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8, 592-603, doi:10.1038/nrc2442 (2008).
74 Jia, H. et al. Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. Thromb Res 163, 105-116, doi:10.1016/j.thromres.2018.01.039 (2018).
75 Dickson, P. V. et al. Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculature. Mol Cancer Res 5, 531-542, doi:10.1158/1541-7786.MCR-06- 0259 (2007).
76 Sidky, Y. A. & Borden, E. C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47, 5155-5161 (1987).
77 Anand, P. K., Malireddi, R. K. & Kanneganti, T. D. Role of the nlrp3 inflammasome in microbial infection. Front Microbiol 2, 12, doi:10.3389/fmicb.2011.00012 (2011).
78 Franchi, L., Muñoz-Planillo, R. & Núñez, G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol 13, 325-332, doi:10.1038/ni.2231 (2012).
79 Saeki, N., Kuwahara, Y., Sasaki, H., Satoh, H. & Shiroishi, T. Gasdermin (Gsdm) localizing to mouse Chromosome 11 is predominantly expressed in upper gastrointestinal tract but significantly suppressed in human gastric cancer cells. Mamm Genome 11, 718- 724, doi:10.1007/s003350010138 (2000).
80 Lamkanfi, M. & Dixit, V. M. Mechanisms and functions of inflammasomes. Cell 157, 1013-1022, doi:10.1016/j.cell.2014.04.007 (2014).
81 Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666-671, doi:10.1038/nature15541 (2015).
82 Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660-665, doi:10.1038/nature15514 (2015).
83 Broz, P., Pelegrín, P. & Shao, F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol 20, 143-157, doi:10.1038/s41577-019-0228-2 (2020).
84 Ding, J. et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111-116, doi:10.1038/nature18590 (2016).
85 Endo, R., Nakamura, T., Kawakami, K., Sato, Y. & Harashima, H. The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy. Sci Rep 9, 11335, doi:10.1038/s41598-019-47799-w (2019).